JP2011510327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510327A5 JP2011510327A5 JP2010544349A JP2010544349A JP2011510327A5 JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5 JP 2010544349 A JP2010544349 A JP 2010544349A JP 2010544349 A JP2010544349 A JP 2010544349A JP 2011510327 A5 JP2011510327 A5 JP 2011510327A5
- Authority
- JP
- Japan
- Prior art keywords
- predetermined value
- subject
- gelsolin
- plasma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 12
- 102000004878 Gelsolin Human genes 0.000 claims 10
- 108090001064 Gelsolin Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 108010085238 Actins Proteins 0.000 claims 4
- 102000007469 Actins Human genes 0.000 claims 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- QQKKFVXSQXUHPI-NBVRZTHBSA-N Acidissiminol epoxide Chemical compound O1C(C)(C)C1CC(O)C(/C)=C/COC(C=C1)=CC=C1CCNC(=O)C1=CC=CC=C1 QQKKFVXSQXUHPI-NBVRZTHBSA-N 0.000 claims 1
- 102000008704 Adseverin Human genes 0.000 claims 1
- 101150107838 Capg gene Proteins 0.000 claims 1
- FCHAMFUEENBIDH-UHFFFAOYSA-N Severin Natural products CC1CCC2C(C)C3CCC4(O)C(CC5C4CC(O)C6CC(CCC56C)OC(=O)C)C3CN2C1 FCHAMFUEENBIDH-UHFFFAOYSA-N 0.000 claims 1
- 102000019215 Supervillin Human genes 0.000 claims 1
- 108050006606 Supervillin Proteins 0.000 claims 1
- 101100440252 Xenopus laevis ncapg gene Proteins 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- -1 fragmin Proteins 0.000 claims 1
- 229940087051 fragmin Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108010073419 scinderin Proteins 0.000 claims 1
- 108090000195 villin Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2378908P | 2008-01-25 | 2008-01-25 | |
| US61/023,789 | 2008-01-25 | ||
| PCT/US2009/000452 WO2009094194A2 (en) | 2008-01-25 | 2009-01-23 | Diagnostic and therapeutic uses of gelsolin in renal failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015005994A Division JP6042915B2 (ja) | 2008-01-25 | 2015-01-15 | 腎不全におけるゲルソリンの診断的および治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510327A JP2011510327A (ja) | 2011-03-31 |
| JP2011510327A5 true JP2011510327A5 (https=) | 2013-08-29 |
| JP5778425B2 JP5778425B2 (ja) | 2015-09-16 |
Family
ID=40901583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544349A Active JP5778425B2 (ja) | 2008-01-25 | 2009-01-23 | 腎不全におけるゲルソリンの診断的および治療的使用 |
| JP2015005994A Active JP6042915B2 (ja) | 2008-01-25 | 2015-01-15 | 腎不全におけるゲルソリンの診断的および治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015005994A Active JP6042915B2 (ja) | 2008-01-25 | 2015-01-15 | 腎不全におけるゲルソリンの診断的および治療的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9575072B2 (https=) |
| EP (2) | EP2708603B1 (https=) |
| JP (2) | JP5778425B2 (https=) |
| CA (2) | CA2749985C (https=) |
| DK (2) | DK2708603T3 (https=) |
| ES (2) | ES2531827T3 (https=) |
| HU (1) | HUE032875T2 (https=) |
| PL (2) | PL2250280T3 (https=) |
| PT (2) | PT2250280E (https=) |
| WO (1) | WO2009094194A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| WO2005046454A2 (en) * | 2003-11-12 | 2005-05-26 | Trustrees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| KR101300929B1 (ko) * | 2004-05-12 | 2013-08-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
| ES2651619T3 (es) * | 2006-03-15 | 2018-01-29 | The Brigham And Women's Hospital, Inc. | Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas |
| KR101556790B1 (ko) | 2006-03-15 | 2015-10-01 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도 |
| US9000134B2 (en) * | 2007-05-11 | 2015-04-07 | Wallace B. Haigh | Reagent and kit for early diagnosis of kidney disease |
| HUE032875T2 (en) | 2008-01-25 | 2017-11-28 | Massachusetts Gen Hospital | Diagnostic and therapeutic applications of gelsolin in renal failure |
| WO2010025128A1 (en) * | 2008-08-25 | 2010-03-04 | Critical Biologics Corporation | Methods for reducing sample size of clinical trials |
| ES2356217B1 (es) * | 2009-08-04 | 2012-02-13 | Universidad De Salamanca | Método para la detección de daño renal. |
| WO2015035405A1 (en) * | 2013-09-09 | 2015-03-12 | Pinta Biotherapeutics, Inc. | Myostatin antagonist for treatment of pew in esrd patients |
| CN104004780A (zh) * | 2014-06-17 | 2014-08-27 | 南京大学 | 一种人胞质凝溶胶蛋白的表达纯化方法 |
| WO2016033187A1 (en) * | 2014-08-26 | 2016-03-03 | The Brigham And Women's Hospital, Inc. | Use of gelsolin in the treatment and diagnosis of sickle cell disease |
| JP6947449B2 (ja) * | 2016-06-29 | 2021-10-13 | 学校法人自治医科大学 | バイオマーカー、診断用組成物、及び診断用キット |
| AU2020296862B2 (en) * | 2019-06-21 | 2025-10-09 | Bioaegis Therapeutics Inc. | Compositions and synergistic methods for treating infections |
| ES3064057T3 (en) * | 2020-05-04 | 2026-04-22 | Bioaegis Therapeutics Inc | Compositions comprising gelsolin for treating frailty |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| CA2016227A1 (en) * | 1989-05-18 | 1990-11-18 | Xandra O. Breakefield | Genetic diagnosis of torsion dystonia |
| JP3616392B2 (ja) | 1990-04-11 | 2005-02-02 | ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド | アクチン結合性化合物の療法的使用 |
| US5464817A (en) | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| CA2063593A1 (en) | 1990-05-04 | 1991-11-05 | Biogen, Inc. | Multimeric gelsolin fusion constructs |
| US5571511A (en) * | 1990-10-22 | 1996-11-05 | The U.S. Government | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5360350A (en) * | 1991-08-23 | 1994-11-01 | The Whitaker Corporation | Sealant compositions and sealed electrical connectors |
| WO1994003601A2 (en) | 1992-08-03 | 1994-02-17 | New York University | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
| US5691160A (en) | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
| EP0675967A4 (en) | 1992-10-01 | 1999-04-28 | Gen Hospital Corp | Functional assay for tumor suppressor genes. |
| US5830436A (en) | 1993-03-30 | 1998-11-03 | Duke University | Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
| US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
| JP3914272B2 (ja) * | 1993-12-28 | 2007-05-16 | 中外製薬株式会社 | アドゼベリンをコードする遺伝子 |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5846743A (en) * | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US5563153A (en) | 1995-02-22 | 1996-10-08 | University Of Kansas Medical Center | Sterile topical anesthetic gel |
| EP0815134B1 (en) | 1995-03-14 | 2002-06-05 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| US5804427A (en) * | 1995-05-19 | 1998-09-08 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| US5925529A (en) * | 1995-06-07 | 1999-07-20 | The Regents Of The University Of California | Method for discovery of peptide agonists |
| US5569588A (en) * | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US5750353A (en) * | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| AU3817497A (en) | 1996-07-30 | 1998-02-20 | Biogen, Inc. | Production of recombinant plasma gelsolin containing a disulfide bond |
| DE69716460T2 (de) * | 1996-12-04 | 2003-06-26 | Renovo Ltd., Manchester | Wundheilung und behandlung von fibrose |
| ATE530180T1 (de) * | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| EP1227847A2 (en) | 1999-10-06 | 2002-08-07 | Basf Aktiengesellschaft | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy |
| WO2002059604A2 (en) | 2001-01-26 | 2002-08-01 | Oxford Glycosciences (Uk) Ltd | Diagnosis and treatment of multiple sclerosis |
| EP1372720A4 (en) | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
| EP1249244A1 (en) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
| EP1414466B1 (en) | 2001-07-09 | 2009-08-19 | CombinatoRx, Incorporated | Combinations for the treatment of inflammatory disorders |
| EP1432728A4 (en) | 2001-08-30 | 2007-10-24 | Praecis Pharm Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
| US20080051348A1 (en) | 2002-02-06 | 2008-02-28 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| AU2003296875B2 (en) | 2002-02-06 | 2008-01-24 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| WO2003088811A2 (en) | 2002-04-16 | 2003-10-30 | The Brigham And Women's Hospital, Inc. | Gelsolin as a prognostic marker of artherosclerotic diseases |
| AU2003253014A1 (en) * | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| EP1627076A4 (en) | 2003-03-14 | 2008-07-02 | Ppd Biomarker Discovery Scienc | BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| WO2005046454A2 (en) | 2003-11-12 | 2005-05-26 | Trustrees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| CA2550833A1 (en) | 2003-12-22 | 2005-07-14 | Regenerx Biopharmaceuticals, Inc. | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| WO2005085859A1 (en) | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
| KR101300929B1 (ko) | 2004-05-12 | 2013-08-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| US20100062471A1 (en) | 2005-09-29 | 2010-03-11 | Ppd Biomarker Discovery Sciences Llc | Biomarkers for Multiple Sclerosis and Methods of Use Thereof |
| ES2651619T3 (es) | 2006-03-15 | 2018-01-29 | The Brigham And Women's Hospital, Inc. | Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas |
| KR101556790B1 (ko) | 2006-03-15 | 2015-10-01 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도 |
| HUE032875T2 (en) | 2008-01-25 | 2017-11-28 | Massachusetts Gen Hospital | Diagnostic and therapeutic applications of gelsolin in renal failure |
| KR101568323B1 (ko) | 2014-01-08 | 2015-11-12 | 한국원자력의학원 | 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법 |
| WO2016033187A1 (en) | 2014-08-26 | 2016-03-03 | The Brigham And Women's Hospital, Inc. | Use of gelsolin in the treatment and diagnosis of sickle cell disease |
-
2009
- 2009-01-23 HU HUE13186249A patent/HUE032875T2/en unknown
- 2009-01-23 EP EP13186249.2A patent/EP2708603B1/en active Active
- 2009-01-23 WO PCT/US2009/000452 patent/WO2009094194A2/en not_active Ceased
- 2009-01-23 DK DK13186249.2T patent/DK2708603T3/en active
- 2009-01-23 DK DK09703176.9T patent/DK2250280T3/en active
- 2009-01-23 CA CA2749985A patent/CA2749985C/en active Active
- 2009-01-23 US US12/358,868 patent/US9575072B2/en active Active
- 2009-01-23 PL PL09703176T patent/PL2250280T3/pl unknown
- 2009-01-23 PL PL13186249T patent/PL2708603T3/pl unknown
- 2009-01-23 CA CA3080273A patent/CA3080273C/en active Active
- 2009-01-23 PT PT09703176T patent/PT2250280E/pt unknown
- 2009-01-23 ES ES09703176.9T patent/ES2531827T3/es active Active
- 2009-01-23 JP JP2010544349A patent/JP5778425B2/ja active Active
- 2009-01-23 ES ES13186249.2T patent/ES2634263T3/es active Active
- 2009-01-23 PT PT131862492T patent/PT2708603T/pt unknown
- 2009-01-23 EP EP09703176.9A patent/EP2250280B1/en active Active
-
2015
- 2015-01-15 JP JP2015005994A patent/JP6042915B2/ja active Active
-
2017
- 2017-01-17 US US15/407,458 patent/US10272136B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510327A5 (https=) | ||
| Samsudin et al. | Clinical utility and measurement of procalcitonin | |
| Kedzierski et al. | Suppressor of cytokine signaling (SOCS) 5 ameliorates influenza infection via inhibition of EGFR signaling | |
| Gao et al. | Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis | |
| Harris et al. | Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD | |
| Harris et al. | Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response | |
| Hoffman et al. | Protein disulfide isomerase–endoplasmic reticulum resident protein 57 regulates allergen-induced airways inflammation, fibrosis, and hyperresponsiveness | |
| WO2012041334A1 (en) | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest | |
| Belknap et al. | The challenges of interstitial cystitis: current status and future prospects | |
| Coudroy et al. | Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis | |
| WO2013143548A1 (en) | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest | |
| Shaker et al. | Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients | |
| Song et al. | C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury | |
| Stefaniak et al. | Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation | |
| Takase et al. | Evaluation of risk for incident hypertension using glomerular filtration rate in the normotensive general population | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| JP2017519008A5 (https=) | ||
| Zhang et al. | Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-κB signaling pathway. | |
| Luna et al. | Senolytic treatment attenuates immune cell infiltration without improving IAV outcomes in aged mice | |
| Parenica et al. | Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality | |
| WO2019023181A1 (en) | METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA | |
| Chen et al. | Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis | |
| Ganesh et al. | Correlation of urinary nephrin with albubinuria to predict early onset of nephropathy in patients with type 2 diabetes mellitus | |
| Maiwall et al. | Acute kidney injury (AKI) in patients with Acute on Chronic Liver failure (ACLF) is different from patients with cirrhosis: 128 | |
| KR100953821B1 (ko) | 비타민 ｄ 결합 단백질을 이용한 천식 진단 마커 및 천식치료제 |